Lysophosphatidic acid and atotaxin in patients with cholestasis and pruritus:Fine biology, anticipated discernment

Annals of Hepatology

Volumn 9, Issue 4, 2010, Pages 475-779

  Bergasa, Nora V ^a  

^a METROPOLITAN HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; CALCIUM ION; LYSOPHOSPHATIDIC ACID; SUBSTANCE P;

ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVATION; CYTOSOL; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAHEPATIC CHOLESTASIS; MASS SPECTROMETRY; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PREGNANT WOMAN; PRIMARY BILIARY CIRRHOSIS; PRURITUS; SCRATCHING;

EID: 79956027148     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31629-1     Document Type: Article

References (33)

1. Lloyd-Thomas HG, Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. Br Med J 1952; 2: 1289-91.
2. Elias E. Liver Transplantation. J Roy Coll Phys London 1993; 27: 224-32.
3. Singh SM, Reber HA. Surgical palliation for pancreatic cancer. Surg Clin North Am 1989; 69: 599-611.
4. Kremer AE, Martens JJ, Kulik W, Rueff F, Kuiper EM, van Buuren HR, van Erpecum KJ, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroente-rology, 139: 1008-18, 1018 e1.
5. Okudaira S, Yukiura H, Aoki J. Biological roles of lysophos-phatidic acid signaling through its production by auto-taxin. Biochimie 2010; 92: 698-706.
6. Mutoh T, Chun J. Lysophospholipid activation of G protein-coupled receptors. Subcell Biochem 2008; 49: 269-97.
7. Renback K, Inoue M, Ueda H. Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neurosci Lett 1999; 270: 59-61.
8. Renback K, Inoue M, Yoshida A, Nyberg F, Ueda H. Vzg-1/ lysophosphatidic acid-receptor involved in peripheral pain transmission. Brain Res Mol Brain Res 2000; 75: 350-4.
9. Cohen A, Sagron R, Somech E, Segal-Hayoun Y, Zilberberg N. Pain-associated signals, acidosis and lysophosphatidic acid, modulate the neuronal K(2P)2.1 channel. Mol Cell Neurosci 2009; 40: 382-9.
10. Ahn DK, Lee SY, Han SR, Ju JS, Yang GY, Lee MK, Youn DH, Bae YC. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 2009; 146: 114-20.
11. Marty A. The physiological role of calcium-dependent channels. Trends Neurosci 1989; 12: 420-4.
12. Pahlman S, Mamaeva S, Meyerson G, Mattsson ME, Bjelf-man C, Ortoft E, Hammerling U. Human neuroblastoma cells in culture: a model for neuronal cell differentiation and function. Act Physiol Scand Suppl 1990; 592: 25-37.
13. Bergasa NV. The pruritus of cholestasis. J Hepatol 2005; 43: 1078-88.
14. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297: 1501-4.
15. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-4.
16. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, et al. Open-label trial of oral nalme-fene therapy for the pruritus of cholestasis. Hepatology 1998; 27: 679-84.
17. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33: 149-60.
18. Ballantyne JC, Loach AB, Carr DB. The incidence of pruritus after epidural morphine. Anaesthesia 1989; 44: 863.
19. Dailey PA, Brookshire GL, Shnider SM, Abboud TK, Kotelko DM, Noueihid R, Thigpen JW, et al. The effects of naloxone associated with the intrathecal use of morphine in labor. Anesth Analg 1985; 64: 658-66.
20. Abbound TK, Lee K, Zhu J, Reyes A, Afrasiabi A, Mantilla M, Steffens Z, et al. Prophylactic oral naltrexone with intra-thecal morphine for cesarean section: effects on adverse reactions and analgesia. Anesth Analg 1990; 71: 367-70.
21. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, et al. A controlled trial of naloxo-ne infusions for the pruritus of chronic cholestasis. Gas-troenterology 1992; 102: 544-9.
22. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Schmitt JM, Walker EC, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomized placebo-controlled trial. Annals of Internal Medicine 1995; 123: 161-7.
23. Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterology 1996; 91: 1022-3.
24. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR. Oral naltrexone treatment for choles-tatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-9.
25. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37: 717-22.
26. Jones EA, Bergasa NV. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 1990; 11: 884-7.
27. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103: 630-5.
28. Barnes LB, Devous MD, Harris TS, Mayo MJ. The central nervous system activity profile of cholestatic pruritus. Hepatolgy 2009; 50: 375 Abstract 153.
29. Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006; 44: 280-1.
30. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 2006; 44: 1317-23.
31. Trivedi M, Bergasa NV. Serum concentrations of substance P in cholestasis. Ann Hepatol 2010; 9: 177-80.
32. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5: e10968.
33. Hashimoto T, Ohata H, Momose K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 2004; 72: 51-6.